United Therapeutics (NASDAQ:UTHR) Bolsa

UNITED THERAPEUTICS CORP

United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

<ul>
<li>This study is the first human clinical trial of a manufactured organ alternative.</li>
<li>The procedure was performed on a patient experiencing liver failure who was not eligible for a liver transplant. The procedure was performed by the team at Intermountain Medical Center in Murray, Utah, led by Christopher J. Danford, MD, a transplant hepatologist at Intermountain Health.</li>
<li>Developed by Miromatrix Medical Inc., a United Therapeutics subsidiary, miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit.</li>
<li>The bioengineered liver is made up of a decellularized porcine liver scaffold to which allogeneic3 human endothelial4 and liver cells have been added.</li>
<li>"This first of its kind treatment represents a historic achievement for United Therapeutics and Miromatrix in advancing the potential of bioengineered human organs to help save and improve patients' lives," said Jeff Ross, Ph.D.,President of Miromatrix. "We're grateful to the patient and their family, in addition to the scientists and caregivers at Intermountain Health and Intermountain Medical Center who helped make this breakthrough possible. Looking ahead, we're excited to continue progressing our ongoing phase 1 clinical trial."</li>
<li>"This groundbreaking procedure – the first of its kind in the world – represents everything Intermountain Health stands for in providing innovative, cutting-edge high-quality care for our patients," said Ralph Jean-Mary, president of Intermountain Medical Center. "We are profoundly thankful to this patient for their participation in this pioneering study, and to our exceptional Intermountain medical team, as well as our partners at United Therapeutics and Miromatrix. This procedure reinforces our unwavering commitment to leading in clinical excellence and helping people live the healthiest lives possible."</li>
<li>United Therapeutics' organ and organ alternative manufacturing efforts consist of three platforms – xenotransplantation,5 allogeneic regenerative medicine, and autologous6 regenerative medicine – encompassing four different organs: hearts, kidneys, livers, and lungs. These revolutionary programs are intended to address the ongoing shortage of transplantable organs for patients with end-stage organ disease.</li>
<li>The investigational miroliverELAP system is not approved for any use in any country.</li>
</ul>

Biotech

News

Health Care

General

UTHR

United Therapeutics And Intermountain Health Announced The World's First Patient Treated In A Clinical Study Of A Bioengineered External Liver Assist Product Called miroliverELAP

United Therapeutics Completes Enrollment Of ADVANCE OUTCOMES Phase 3 Study For Ralinepag, A Once-Daily Oral PAH Therapy

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) stock fell 13.67% last week after reporting mixed <a href="https://www.benzinga.com//node/45862389" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a> and issuing fiscal year 2026 EPS guidance below expectations. Multiple analysts also <a href="https://www.benzinga.com/quote/SJM/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered their price forecasts</a>.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) stock fell 13.57% last week after the company issued a lower-than-expected <a href="https://www.benzinga.com//node/45885618" target="_blank" rel="noreferrer noopener">fiscal year 2025 sales outlook</a> despite strong first-quarter earnings. Analysts responded by revising <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings" target="_blank" rel="noreferrer noopener">their forecasts downward</a>.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) stock declined 13.06% after reporting its <a href="https://www.benzinga.com//node/45803479" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) stock dropped 13.03% last week. The stock reacted negatively to positive trial results from rival Insmed. BofA Securities also <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered its price forecast</a> to $315 while maintaining a Neutral rating.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) stock plunged 13.01% last week following bearish options activity and a <a href="https://www.benzinga.com//node/45932268" target="_blank" rel="noreferrer noopener">notable insider sale</a>.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock sank 12.78% last week. The decline followed a <a href="https://www.benzinga.com//node/45910389" target="_blank" rel="noreferrer noopener">short report</a> issued by Culper Research.</li>
<li>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) stock lost 12.15% last week. Rising fuel prices after Israel's strikes on Iran pressured airline stocks, and a recent Air India crash may have also weighed on sector sentiment.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) stock fell 11.61% last week.</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) stock fell 10.12% after Wolfe Research <a href="https://www.benzinga.com/quote/EIX/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a> from Outperform to Peer Perform.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) stock fell 9.86% last week. The company <a href="https://www.benzinga.com//node/45899298" target="_blank" rel="noreferrer noopener">continued its decline</a> after its first-quarter earnings, as several analysts downgraded the stock and <a href="https://www.benzinga.com/quote/LULU/analyst-ratings" target="_blank" rel="noreferrer noopener">revised their price forecast</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares fell 9.72% last week after Goldman Sachs <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded its rating</a> on the stock from Buy to Neutral.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45940507/oracle-ast-spacemobile-and-halliburton-are-among-top-10-large-cap-gainers-last-week-june-9-13-are-the-others-in-your-portfolio">Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Large Cap

Movers

Trading Ideas

CHWY

CVNA

GRAB

LULU

MBLY

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Neutral and lowers the price target from $321 to $315.

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $315

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday.
The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S&amp;P 500 also rose, gaining, 0.29% to 6,023.46.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a>
Leading and Lagging Sectors Energy shares jumped by 1.9% on Tuesday.
In trading on Tuesday, industrials stocks fell by 0.4%.
Top Headline
The NFIB Small Business Optimism Index rose to 98.8 in May from 95.8 in April and topping market estimates of 95.9.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) shares shot up 27% to $89.94 after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all secondary efficacy endpoints.</li>
<li>Shares of Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) got a boost, surging 15% to $506.20 after the company reported better-than-expected fourth-quarter financial results and increased its quarterly dividend.</li>
<li>Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) shares were also up, gaining 72% to $1.9399. Evogene announced completion of first-in-class foundation model for generative molecule design, developed in collaboration with Google Cloud.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) shares dropped 21% to $14.23 in reaction to Insmed&#8217;s drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.</li>
<li>Shares of Calavo Growers, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) were down 17% to $22.93 after the company reported worse-than-expected second-quarter financial results.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) was down, falling 16% to $276.38 in reaction to Insmed after its drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $65.14 while gold traded down 0.3% at $3,344.80.
Silver traded down 0.6% to $36.570 on Tuesday, while copper fell 0.5% to $4.8990.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.09%, while Spain's IBEX 35 Index rose 0.19%. London's FTSE 100 gained 0.45%, Germany's DAX 40 fell 0.35% and France's CAC 40 rose 0.09% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.32%, Hong Kong's Hang Seng Index falling 0.08%, China's Shanghai Composite dipping 0.44% and India's BSE Sensex falling 0.07%.
Economics
The NFIB Small Business Optimism Index rose to 98.8 in May from 95.8 in April and topping market estimates of 95.9.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CASY

CVGW

EVGN

INSM

LQDA

Dow Gains 50 Points; US Small Business Optimism Index Rises In May

WIIM

United Therapeutics shares are trading lower in reaction to Insmed after its drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.

<h3>Gainers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 115.4% to $1.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock rose 84.56% to $0.42. The company's market cap stands at $17.4 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares moved upwards by 56.47% to $2.66. The company's market cap stands at $25.1 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 41.77% to $2.58. The company's market cap stands at $83.8 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 23.78% to $2.03. The company's market cap stands at $128.0 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 21.39% to $0.09. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares fell 48.9% to $0.46 during Tuesday's pre-market session. The company's market cap stands at $55.4 million. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock declined by 24.82% to $1.03. The market value of their outstanding shares is at $10.5 million. </li>
<li>Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) stock decreased by 16.99% to $14.96. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock fell 14.14% to $2.61. The company's market cap stands at $19.5 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) stock declined by 12.3% to $288.02. The market value of their outstanding shares is at $12.9 billion. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock declined by 11.39% to $1.09. The market value of their outstanding shares is at $77.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARM

CTOR

CTXR

GELS

KLTO

MGNX

NCNA

UNCY

WINT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

In the last three months, 7 analysts have published ratings on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $358.71, a high estimate of $425.00, and a low estimate of $314.00. A decline of 1.81% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748872832_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of United Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$348.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$314.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$357.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$314.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into United Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Get to Know United Therapeutics Better</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: United Therapeutics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 17.22%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.86% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For United Therapeutics

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight rating and announces Price Target of $405.

Initiation

Cantor Fitzgerald Initiates Coverage On United Therapeutics with Overweight Rating, Announces Price Target of $405

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">improve exercise ability</a>.
In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40752393/fda-battles-backlog-of-drug-factory-inspections-since-covid-19" rel="noreferrer noopener">FDA Battles Backlog of Drug Factory Inspections Since COVID-19</a>
Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia&#8217;s proprietary PRINT technology, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45593900/u-s-fda-approves-liquidias-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-art" rel="noreferrer noopener">less inspiratory effort</a>.
The approval of Yutrepia is based on findings from the Phase 3 INSPIRE trial, which evaluated patients who were naïve to treprostinil and those transitioning to Yutrepia from nebulized treprostinil.
Yutrepia was shown to be safe and well-tolerated regardless of a patient&#8217;s previous exposure to treprostinil.
As previously disclosed, United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) filed a complaint on May 9, in the U.S. District Court for the Middle District of North Carolina against Liquidia, alleging infringement of U.S. Patent No. 11,357,782. The complaint seeks to enjoin Liquidia from commercializing Yutrepia <a href="https://www.benzinga.com/pressreleases/25/05/g45593900/u-s-fda-approves-liquidias-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-art" target="_blank" rel="noreferrer noopener">to treat PAH and PH-ILD</a>.
United Therapeutics has filed a motion for a temporary restraining order and preliminary injunction to block Liquidia from commercially launching Yutrepia. An oral argument on the motion was held on May 20, 2025. The motion remains pending with the Court.
In March, Liquidia&nbsp;entered into a sixth amendment to its agreement with HealthCare Royalty to provide up to an additional&nbsp;$100 million of financing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45279833/liquidia-corporation-reports-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">in three tranches</a>.&nbsp;
The company&nbsp;intends to use the proceeds to fund ongoing commercial development of Yutrepia, continued development of Yutrepia in other clinical trials, including but not limited to trials for pediatric patients, and trials further evaluating the use of Yutrepia in&nbsp;PAH and PH-ILD patients, clinical development of L606, a sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and for general corporate purposes.
Price Action: LQDA stock is down 3.3% at $14.84 on the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45614776/why-is-prothena-stock-trading-lower-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Prothena Stock Trading Lower On Tuesday?</a></li>
</ul>
Photo: Shutterstock

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

<ul>
<li>Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
<li>The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB's decision was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;in&nbsp;December 2023. The United States Supreme Court&nbsp;rejected UTHR's petition for a writ of certiorari, thereby upholding PTAB's decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.</li>
<li>UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.</li>
</ul>

Legal

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $425 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $425 Price Target

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and lowers the price target from $355 to $350.

JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $350

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Equal-Weight and raises the price target from $346 to $348.

Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $348

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.63 per share which beat the analyst consensus estimate of $6.52 by 1.69 percent. This is a 7.46 percent increase over earnings of $6.17 per share from the same period last year. The company reported quarterly sales of $794.40 million which beat the analyst consensus estimate of $729.83 million by 8.85 percent. This is a 17.22 percent increase over sales of $677.70 million the same period last year.

Earnings Beats

United Therapeutics Q1 EPS $6.63 Beats $6.52 Estimate, Sales $794.40M Beat $729.83M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Eric Joseph initiated coverage on OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Neutral rating. OPKO Health shares closed at $1.46 on Thursday. <a href="https://www.benzinga.com/quote/OPK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Asiya Merchant initiated coverage on Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral rating and announced a price target of $39. Super Micro Computer shares closed at $35.81 on Thursday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Rich Kwas initiated coverage on Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with an Equal-Weight rating and announced a price target of $20. Sensata Technologies shares closed at $21.64 on Thursday. <a href="https://www.benzinga.com/quote/ST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li> Needham analyst Ryan Koontz initiated coverage on Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy rating and announced a price target of $28. Rocket Lab USA shares closed at $21.88 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OPK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png" alt="" class="wp-image-888690" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

RKLB

SMCI

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Joseph Vafi downgraded the rating for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from Buy to Hold and lowered the price target from $115 to $55. ASGN shares closed at $51.76 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev downgraded SS&amp;C Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) from Overweight to Neutral and lowered the price target from $90 to $86. SS&amp;C Technologies shares closed at $77.43 on Thursday. <a href="https://www.benzinga.com/quote/SSNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Linda Huang downgraded the rating for TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) from Outperform to Neutral and cut the price target from $14.5 to $10.9. TAL Education shares closed at $8.93 on Thursday. <a href="https://www.benzinga.com/quote/TAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Tiago Fauth downgraded United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and slashed the price target from $395 to $314. United Therapeutics shares closed at $296.42 on Thursday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UTHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png" alt="" class="wp-image-888521" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173.png 1065w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

ASGN

SSNC

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Across the recent three months, 4 analysts have shared their insights on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% decrease from the previous average price target of $372.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582487_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tiago Fauth &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $314.00&#x7C;$395.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $355.00&#x7C;$357.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;B of A Securities &#x7C;Maintains &#x7C;Neutral &#x7C; $314.00&#x7C;$314.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $425.00&#x7C;$425.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into United Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining United Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.72% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 40.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.16%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying United Therapeutics: Insights From 4 Analyst Reviews

Wells Fargo analyst Tiago Fauth downgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and lowers the price target from $395 to $314.

Wells Fargo Downgrades United Therapeutics to Equal-Weight, Lowers Price Target to $314

Press Releases

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

United Therapeutics Corporation Reports First Quarter 2025 Financial Results

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver

Comments

United Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL